STOCK TITAN

Vanguard (TWST) amendment shows 0 shares after Jan 12, 2026 realignment

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting 03/13/2026 activity for Twist Bioscience Corp common stock. The filing states that, after an internal realignment effective 01/12/2026, certain Vanguard subsidiaries will report ownership separately under SEC Release No. 34-39538. The filing shows amount beneficially owned: 0 and percent of class: 0%. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports zero beneficial ownership in TWST after internal disaggregation.

The amendment documents an internal realignment dated 01/12/2026 and states subsidiaries will report separately in reliance on SEC Release No. 34-39538. The filing explicitly lists 0 shares beneficially owned and 0% of the class.

This indicates the reporting aggregation changed; subsequent Schedule 13G/A filings by Vanguard entities may show holdings. Follow future filings for any reappearance of Vanguard-affiliated holdings.

Amendment clarifies reliance on SEC Release No. 34-39538 for disaggregated reporting.

The document cites Release No. 34-39538 and explains that certain subsidiaries or business divisions will report separately. It affirms Vanguard no longer is deemed to beneficially own securities held by those subsidiaries after the realignment.

Signature block shows Ashley Grim signed on 03/27/2026. Future filings by the named subsidiaries should be checked for any reported positions.






90184D100

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does Vanguard's Amendment No. 5 say about its holdings in TWST?

The amendment states amount beneficially owned: 0 and percent of class: 0%. It reports an internal realignment and disaggregation under SEC Release No. 34-39538, with subsidiaries to report separately effective 01/12/2026.

Why is Vanguard reporting separate holdings after the January 12, 2026 realignment?

Vanguard explains it underwent an internal realignment on 01/12/2026 and, per SEC Release No. 34-39538, certain subsidiaries will report beneficial ownership separately rather than under The Vanguard Group, Inc.

Who signed the Schedule 13G/A amendment for Vanguard regarding TWST?

The amendment is signed by Ashley Grim, listed as Head of Global Fund Administration, with the signature date shown as 03/27/2026 on the filing cover information.

Does the filing indicate Vanguard still controls dividends or sale proceeds for TWST shares?

The filing states that Vanguard, including registered investment companies and managed accounts, has the right to receive or direct dividends or sale proceeds when applicable, but here it reports no beneficial ownership in TWST.

Will Vanguard or its subsidiaries file further reports for TWST?

The amendment indicates subsidiaries will report separately in reliance on Release No. 34-39538; subsequent Schedule 13G/A or similar filings by those subsidiaries may disclose holdings if any are acquired.
Twist Bioscience

NASDAQ:TWST

View TWST Stock Overview

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.87B
60.41M
Diagnostics & Research
Biological Products, (no Diagnostic Substances)
Link
United States
SOUTH SAN FRANCISCO